摘要：SummaryMASTL is a mitotic accelerator with an emerging role in breast cancer progression. However, the mechanisms behind its oncogenicity remain largely unknown. Here, we identify a previously unknown role and eminent expression of MASTL in stem cells. MASTL staining from a large breast cancer patient cohort indicated a significant association with β3 integrin, an established mediator of breast cancer stemness. MASTL silencing reduced OCT4 levels in human pluripotent stem cells and OCT1 in breast cancer cells. Analysis of the cell-surface proteome indicated a strong link between MASTL and the regulation of TGF-β receptor II (TGFBR2), a key modulator of TGF-β signaling. Overexpression of wild-type and kinase-dead MASTL in normal mammary epithelial cells elevated TGFBR2 levels. Conversely, MASTL depletion in breast cancer cells attenuated TGFBR2 levels and downstream signaling through SMAD3 and AKT pathways. Taken together, these results indicate that MASTL supports stemness regulators in pluripotent and cancerous stem cells.Graphical abstractDisplay OmittedHighlights•MASTL displays positive correlation with β3 integrin expression in breast tumors•MASTL is enriched in human pluripotent stem cells and breast cancer stem cells•Depletion of MASTL leads to decline of stemness indicators OCT1, OCT4, and NANOG•MASTL supports TGF-β receptor II expression and activation of SMAD3 and AKTCell biology; Stem cells research; Cancer; Proteomics
